Skip to main content
. 2015 Jan 19;7(1):268–284. doi: 10.3390/v7010268

Table 1.

Examples of ligand and transcriptional targeting used in eukaryotic viral vectors in targeted cancer therapy.

Vector Tumor-Specific Promoters Ligand Targeting References
Ad PSA, GH, TRE, rTG, AFP, VEGFR-2, flt-1, hTERT RGD, NGR, SIGYPLP, CGKRK, SIKVAV [13,15,16,17,18,19]
AAV PRC1, RRM2, BIRC5 NGR, GFE [20,21]
HSV-1 Albumin, ANGPTL-3, E2F-1 ND * [9,22]
LV PSA/E αCD20, hSCF [17,23]
RV CEA, GRP78, kdr, E-selectin ND * [17,24,25]
MV ND * HSNS, HAA [26]

AAV: adeno-associated virus; ANGPTL-3: human angiopoietin-like 3; BIRC5: Baculoviral IAP repeat-containing 5; E2F-1: transcription factor 1; GH: Growth hormone; PSA/E: Prostate-specific antigen/Enhancer; hSCF: human stem cell factor; HSNS/HAA: modified attachment protein H on MV; LV: lentivirus; MV: measles virus vector; PRC1: protein regulator of cytokinesis 1; RRM2: ribonucleotide reductase subunit 2; rTG: rat thyroglobulin; SIGYPLP, CGKRK, SIKVAV: homing peptides; RV: retrovirus; TRE: Tetracyclin response element; VEGFR2: Vascular endothelial growth factor receptor 2; * ND: Not determined.